ArticleInternational ophthalmology2025
Association between serous macular detachment and choroidal vascular architecture in treatment-Naïve branch retinal vein occlusion.
Article in International ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeBranch retinal vein occlusion (BRVO) is a common retinal vascular disorder that can cause visual impairment through macular edema and ischemia. The primary aim of this study was to investigate choroidal structural changes in treatment-naïve BRVO patients. The secondary aim was to assess the impact of serous macular detachment (SMD) on choroidal parameters.
methodsThis single-center, retrospective cross-sectional study included 88 patients with unilateral BRVO. Eyes with BRVO, fellow eyes, and age- and sex-matched controls were classified as Groups 1, 2, and 3, respectively; Group 1 was further subdivided by SMD presence. Choroidal assessment included best-corrected visual acuity (BCVA), central macular thickness (CMT), subfoveal and parafoveal choroidal thicknesses-subfoveal choroidal thickness (SFCT), subfoveal nasal choroidal thickness (SFNCT), subfoveal temporal choroidal thickness (SFTCT), submacular nasal choroidal thickness (SMNCT), and submacular temporal choroidal thickness (SMTCT)-and choroidal vascularity index (CVI). Group comparisons used Student's t-test or Mann-Whitney U test for two groups, and one-way ANOVA or Kruskal-Wallis test for three groups. Correlations were analyzed using Pearson or Spearman coefficients. p < 0.05 was considered significant.
resultsGroup 1 (BRVO eyes) showed significantly lower subfoveal and submacular CVI values compared with Groups 2 (fellow eyes) and 3 (controls) (p < 0.001). SFCT was significantly higher in Group 1 than in Groups 2 and 3 (p < 0.001 and p = 0.004, respectively). Within Group 1, eyes with SMD had lower BCVA and subfoveal CVI than those without SMD (p = 0.003 and p = 0.009, respectively).
conclusionOur findings suggest that in BRVO, the presence of SMD may be associated with reduced subfoveal CVI (SFCVI), indicating potential choroidal vascular alterations that may vary according to the type of macular edema. These observations warrant further investigation and may guide future, more comprehensive studies to better understand BRVO pathophysiology.
Indexed as
Identifiers
41405644What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.